WeightWatchers’ CEO embraced Ozempic. Now she’s out of the company.

Sima Sistani, who stepped down Friday, helped push WW International to embrace weight-loss drugs.

It’s been a bumpy year for WW International, the company also known as WeightWatchers.

In a leadership shake-up Friday, the weight-loss company announced CEO Sima Sistani is stepping down after roughly two years — effective immediately — and the board member Tara Comonte is stepping up to serve as interim chief.

“On behalf of the Board, I want to sincerely thank Sima for her leadership in advancing our strategy, for adding WeightWatchers Clinic to our offerings, and for her unwavering commitment to our mission,” Thilo Semmelbauer, the chair of the board of directors, said. “We wish her all the best in her future endeavors.”

Sistani helped push the company into the weight-loss drug space in 2023 through the $106 million acquisition of the telehealth platform Sequence — now called WeightWatchers Clinic, which prescribes weight-loss drugs like Ozempic and Wegovy.

“What we do best is help people with weight management. That is the anchor,” Sistani told CNN in November. “I think we have to be true and authentic to that and who we are.”

The telehealth purchase marked something of a pivot from the group support meetings and calorie-tracking menus WeightWatchers is known for, though the company also launched a behavioral program for patients on Ozempic.

In her CNN interview, Sistani said it was important for WeightWatchers to be clear that obesity is a chronic condition — one that certain people can treat with medication.

“It’s not willpower alone,” she said. “And what we are now saying is we know better and it’s on us to do better so that we can help people feel positive and destigmatize this conversation around obesity.”

But the changes at WeightWatchers haven’t seemed to woo investors.

Shares have plunged about 90% year to date, trading at record lows under $1 in August after reporting disappointing quarterly results.

WW International said Comonte, who’s held roles at TMRW Life Sciences and Shake Shack, would work to “sharpen its strategic focus, and evolve its behavioral and clinical offerings to drive growth.”

In a statement, Comonte said she looked forward to advancing WW International’s mission “during this critical period of our transformation.”

WW International did not immediately respond to a request for comment from B-17.

Weight-loss drugs have upended the industry, with several healthcare companies seeking to capitalize on the hype of the effective, expensive medication.

WW International took a hit earlier this year when Oprah Winfrey, a longtime shareholder and board member, said she was stepping down and donating her shares to the Smithsonian’s National Museum of African American History and Culture.